Diagnosis, Treatment Patterns, and Outcomes in Real-World Patients with RET Fusion-Positive Non-small Cell Lung Cancer in China.

Autor: Lu S; Department of Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai, 200000, China. shun.lu@me.com., Shen L; Department of Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai, 200000, China., Wang Q; Department of Oncology, Henan Cancer Hospital, Zhengzhou, China., Chen H; Department of Oncology, Henan Cancer Hospital, Zhengzhou, China., Zhao Y; Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China., Li Y; Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China., Segall G; Eli Lilly and Company, Bracknell, UK., Khanal M; Eli Lilly and Company, Indianapolis, IN, USA., Zhang X; Eli Lilly and Company, Shanghai, China., Ding D; Eli Lilly and Company, Shanghai, China., Shao J; Eli Lilly and Company, Shanghai, China., Pang L; Real-World Solutions, IQVIA, Shanghai, China.
Jazyk: angličtina
Zdroj: Advances in therapy [Adv Ther] 2024 Nov; Vol. 41 (11), pp. 4248-4265. Date of Electronic Publication: 2024 Sep 24.
DOI: 10.1007/s12325-024-02983-x
Abstrakt: Introduction: Epidemiological studies on non-small cell lung cancer (NSCLC) have noted RET fusions as an oncogenic driver. However, real-world data on RET biomarker testing and treatment patterns in China remain limited. This study aimed to examine demographics, clinical and molecular features, and RET testing and treatment patterns and outcomes in patients with RET fusion-positive NSCLC.
Methods: Utilizing real-world data from the Chinese Multi-center Lung Cancer Precision Medicine Registry, this retrospective cohort study focused on Chinese patients diagnosed with RET fusion-positive NSCLC between January 1, 2016, and November 30, 2021. The cohort was divided into early-stage and advanced-stage subgroups. Demographics, clinical and molecular profiles, treatment received, and outcomes including real-world event free survival (rwEFS), real-world progression free survival (rwPFS), and overall survival (OS) were assessed.
Results: The study included 121 patients with RET fusion-positive NSCLC, comprising 80 early-stage and 58 advanced-stage patients. High biomarker testing rates were observed at diagnosis (75% for early-stage, 78% for advanced-stage). RET testing was often conducted via tissue samples (95.9%) and next-generation sequencing (89.3%). KIF5B (57.0%) and CCDC6 (20.7%) were the most common gene fusion partners. The most frequent oncogenic mutations were TP53 (15.7%) and EGFR (6.6%). Platinum-based chemotherapy was the most common first-line treatment among advanced-stage patients. Median rwPFS was 9.22 months for advanced-stage patients on first-line chemotherapy, and median OS was 30.7 months for all advanced-stage patients. The 2-year rwEFS rate for early-stage patients was 86.0%, with a median OS of 91.9 months.
Conclusions: The study observed high biomarker testing rates at initial diagnosis for early- and advanced-stage RET fusion-positive NSCLC patients in China. The heterogeneous treatment pattern of advanced patients suggests the need for more precise, evidence-based treatment to guide clinical decisions. Given the existing therapeutic regimens fall short of adequately addressing treatment needs, targeted therapies are essential to improve outcomes.
(© 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: